- $24.39bn
- $20.57bn
- $5.14bn
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Incyte makes $2 billion bet on bleeding disorder drug ahead of Jakafi patent cliff (updated)
Brief: Incyte To Acquire Vega Therapeutics, A Wholly Owned Subsidiary Of Star Therapeutics, Expanding Its Hematology Portfolio Into Bleeding Disorders
Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary
Deals of the day-Mergers and acquisitions
Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports
Brief: Incyte Nears Up To $2 Billion Deal For Blood Disorder Biotech Star - FT
Brief: Incyte Says Frontmind Trial Shows 25% Reduction In Disease Progression Or Death In High-Risk Dlbcl
Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Brief: Incyte And Genesis Expand Molecular Ai Collaboration To Accelerate Drug Discovery
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Incyte beats first-quarter estimates on strong demand for cancer drugs
Biopharma firm Incyte's Q1 revenue, adjusted profit beat estimates
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Incyte's skin disease drug shows long-term symptom relief in late-stage trials
Brief: Incyte Announces Executive Leadership Appointments
Karyopharm jumps as blood cancer drug meets one of two main goals in study